One of the most rapidly fast-tracked vaccines in history— an anti-Ebola “ChAd3” vaccine— just started clinical trial in humans, and may be done as soon as November. But a second fast-tracked anti-Ebola vaccine— called an “rVSV” vaccine— is hot on its heels.
Children with sensory processing disorder (SPD) have decreased white matter brain connections in...
There have been stunning “firsts” in research on idiopathic pulmonary fibrosis (IPF), a...
When cancers spread into the bloodstream, they often take on different characteristics,...
ZMapp, an experimental drug that may have already have saved a few patients in Africa, is the most effective anti-Ebola therapy yet, according to a recent Nature paper on rhesus macaques monkeys.
Riken Center for Developmental Biology (CDB), the prominent Japan institute where Haruko Obokata was found to commit misconduct on stem cell papers, will be halved, according to a Riken representative.
At first blush it is a bit disingenuous, using beer waste as a base material for new bone. But that is exactly what a multidisciplinary team of researchers in Spain has come up with in a process for making the substrate material on which bone can be regenerated.
As, all around them, everyone from Derek Jeter to the Kennedy family was dousing themselves in ice water for the ALS “Ice Bucket Challenge,” Harvard researchers announced last week they may have found an ALS therapy— or two.
A large new study found that when post-menopausal women stop physical activity, their odds of developing breast cancer rise. But, the study also found that breast cancer risk drops surprisingly rapidly after exercise starts.
The birth control pill significantly affects ovarian reserve— or the number of immature eggs in a woman’s ovaries— which can be a predictor of future fertility, according to a team in Denmark.
Two recent studies— one human, one mouse— have found cloning creates better pluripotent stem cells than the Nobel Prize-winning induced pluripotent stem cell (iPSC) method. A third study also came out supporting the conclusions.
In two months, the first of many new Parkinson’s disease (PD) patients will receive a fetal cell transplant. The transplant will mark the end of a voluntary moratorium by many Western nations after complications arose a decade ago. This, combined with news that embryonic stem (ES) cell PD therapies may also near prime-time, made Parkinson’s a big topic at the recent International Society for Stem Cell Research (ISSCR) meeting.
Many promising clinical trials were highlighted at the annual meeting of the International Society of Stem Cell Research (ISSCR). One set of trials highlighted were monogenic gene therapy trials and cancer immunotherapy trials. Also discussed were trials for Parkinson’s disease, Multiple Sclerosis, and potential future trials involving cochlear stem cells.
What we currently know about aging is not highly specific; our cells divide many times throughout our lives and eventually cause organs and our bodies to age, break down and fail. New research, however, suggests that how we age might depend on cellular interactions that we inherit from our ancestors, accumulating throughout many generations.
Just as Nature was setting about retracting two famous Riken CDB papers claiming to make “STAP” stem cells from ordinary cells, another Riken researcher said she might suspend a world-first clinical trial of a competing—legitimate—stem cell technique. But within hours, she modified her views, according to Riken.
At 21, MS had Jennifer Molson “wheelchair bound.” But since her stem cell transplant, she has worked, driven, danced at her own wedding. The story had a room of 1,000 professional stem cell scientists sniffling loudly at the International Society for Stem Cell Research (ISSCR) meeting—said sniffling reaching a crescendo when the quiet, pretty Molson concluded: “I’m living proof stem cells can save lives.”
As Nobel Prize-winning scientist Shinya Yamanaka regaled a New York crowd with advances that may send his Japanese institute to the top of the global stem cell field, investigators in Tokyo said the stem cell division at his sister institute is so wracked with problems it should dismantle—or dramatically revamp.
Everyone loves a grand slam: the crack of the bat, the arc of the ball as it sails over the fence, a tip of the batter’s cap, a triumphal trot around as the bases empty out, but really, it’s the lesser efforts that made it all possible—a double, a single, a walk—it’s the incremental gains that win the game. It’s called Small Ball. This year’s ASCO, absent the heavy hitters, was all about the small ball.
Federal funding for cancer research has diminished over the last ten years, and the negative impact on research is now apparent. There were no blockbuster revelations, no flashy new kid on the block, no miracle cures at this year’s ASCO. Of the four studies selected for the plenary session (where presentations are often THE important findings of the conference), only one is predicted to have a major impact on patient care.